PA LOS JEITER W/ @rozzausa

he who causes heart murmurs and pancreatic failure to those who stare too long... type AMEN ❤️ to undo 25 years of bad luck...

++##PancreaticFailure

Emergency medicine has been the safety net for the medical system for years, but is the only access point for many across this country. We are also seeing rising incidence of diabetes in all ages. As a result, emergency medicine has the opportunity to play a role in screening and detection with the goal of risk and complication prevention. In this episode, we talk with Dr. James Paxton on our opportunities and some tools we can use to support our patients and improve their outcomes. 

Supported by Sanofi US

So Sweet...Type 1 Diabetes Screening in the ED with Dr. James Paxton

🎙️✨ O novo episódio do OncoPonto está imperdível!

Desta vez, discutimos sobre o câncer de pâncreas, um tema desafiador que tem avançado rapidamente graças à ciência e ao trabalho multidisciplinar.

Moderado pela Dra. Débora Curi, oncologista do Grupo SOnHe, o episódio traz uma conversa esclarecedora e cheia de insights com especialistas renomados:

Dr. Hugo Hammoud, cirurgião oncológico
Dr. Lucas Oliveira, cirurgião oncológico
Dr. Rafael Mello, cirurgião do aparelho digestivo

Entenda os desafios e os mais recentes avanços no tratamento e diagnóstico dessa doença.

👉 Já disponível no Spotify e no Youtube do Grupo SOnHe!

Câncer de Pâncreas:Desafios e Avanços Recentes

This song is a heartfelt tribute to early detection and the power of artificial intelligence and modern science. Inspired by the real-life stories of patients who discovered cancer at its earliest—and most treatable—stage, “I Took the Test (And I'm Still Here)” brings a message of hope, not fear.

As a physician, I’ve seen firsthand the difference it makes when cancer is found before symptoms ever appear. The Galleri® test is a multi-cancer early detection tool that can identify signals for dozens of cancers through a simple blood draw—many of which don’t have routine screening options.

This isn’t a song about worry. It’s about being proactive, about giving yourself and your loved ones more time, more options, and more life.

I hope this song opens up a conversation. Because sometimes the best way to treat cancer… is to catch it before it starts to shout.

Took the Test (And I'm Still Here)

BUFFALO, NY — June 17, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 5, on May 1, 2025, titled “Oxytocin modulates insulin and GLP-1 secretion in pancreatic islets.”

In this study, scientists from Fukushima Medical University School of Medicine investigated how the hormone oxytocin (Oxt) influences insulin levels by acting on specific cells in the pancreas. The team led by first author Kasumi Hattori and corresponding authors Kenju Shimomura and Yuko Maejima discovered that oxytocin may indirectly increase insulin secretion by triggering another hormone, GLP-1, from within the pancreas. This finding could lead to new strategies for improving blood sugar control in people with diabetes.

Oxytocin is commonly known for its roles in childbirth and social bonding, but scientists have also been exploring its effects on metabolism. While previous studies offered mixed results about whether oxytocin raises or lowers blood sugar, this research brings new clarity. The study focused on oxytocin’s impact on insulin and a hormone called GLP-1, which helps regulate insulin production. Researchers tested this by using mice with and without oxytocin receptors and found that oxytocin’s ability to raise insulin levels depended on the presence of these receptors and high blood sugar conditions.

Researchers found that oxytocin stimulates the release of “intra-islet GLP-1,” a form of GLP-1 produced inside the pancreas rather than the intestine. In the pancreas, insulin is produced by beta cells, while alpha cells produce glucagon, a hormone that raises blood sugar. But recent research, including this study, has shown that alpha cells can also release GLP-1, which in turn helps beta cells secrete insulin. Oxytocin appears to increase this internal GLP-1 release, especially when blood sugar levels are high, thereby leading to insulin release in a natural and targeted way.

In this study researchers were also able to detect the difference between oxytocin’s effect on blood sugar and its effect on insulin. They observed that right after oxytocin was given, blood sugar levels rose in all mice—even in those that lacked oxytocin receptors. However, only the mice with working oxytocin receptors showed a later increase in insulin. This suggests that oxytocin may trigger insulin production through a separate, receptor-dependent pathway involving the hormone GLP-1.

"WT mice showed a significant increase in insulin levels at 15-min, while OxtR KO mice did not."

This indirect action—oxytocin triggering alpha cells to release GLP-1, which then acts on beta cells—may represent a novel mechanism for controlling insulin release. It also explains why oxytocin does not increase insulin in low-glucose conditions, making it a potentially safer option for regulating blood sugar.

As treatments for type 2 diabetes increasingly focus on GLP-1–based drugs, this study opens the door to using oxytocin or similar compounds to naturally enhance the body’s own insulin-producing system. With further research, this mechanism could help develop new therapies that better mimic the body’s natural glucose control, particularly beneficial for older adults with diabetes.

DOI - https://doi.org/10.18632/aging.206244

Corresponding authors - Kenju Shimomura - shimomur@fmu.ac.jp, and Yuko Maejima - maejimay@fmu.ac.jp

Video short - https://www.youtube.com/watch?v=C0K6uDX4z8U

To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at:

Facebook - https://www.facebook.com/AgingUS/
X - https://twitter.com/AgingJrnl
Instagram - https://www.instagram.com/agingjrnl/
YouTube - https://www.youtube.com/@AgingJournal
LinkedIn - https://www.linkedin.com/company/aging/
Bluesky - https://bsky.app/profile/aging-us.bsky.social
Pinterest - https://www.pinterest.com/AgingUS/
Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc

MEDIA@IMPACTJOURNALS.COM

Aging (Aging-US)

New Hormonal Pathway Links Oxytocin to Insulin Secretion in the Pancreas

BUFFALO, NY - June 17, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on June 10, 2025, titled “Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence.”

The study, led by first author Kavin Sugumar and corresponding author Jordan M. Winter, from University Hospitals Seidman Cancer Center, reports on a rare group of pancreatic cancer (PC) patients who responded remarkably well to immunotherapy, a treatment typically considered ineffective for this cancer type. The analysis, which includes data from 14 patients across multiple U.S. institutions, identifies outcomes that could help refine treatment strategies for one of the most aggressive and deadly forms of cancer.

“Between 2020–21, 471 oncologists from 91 major cancer centers in the United States were contacted.”

Pancreatic cancer has among the lowest survival rates and few effective therapies. While immunotherapy has transformed the treatment landscape for several other cancers, it generally offers little benefit for pancreatic cancer. However, this study highlights a small but important group of patients who experienced significant and sustained responses to immune-based treatment without chemotherapy. Most had advanced or metastatic disease and had already progressed after standard treatments.

Among the 14 patients, 82% had partial tumor shrinkage, and nearly one-third had a notable decrease in tumor markers. The median progression-free survival was 12 months, and most patients were still alive at follow-up, with survival rates of 80% at one year and 70% at two years. These outcomes contrast sharply with standard therapies, which often provide only a few months of benefit for similar patients.

Interestingly, while some patients had high microsatellite instability (MSI-high)—a known marker for immunotherapy success—more than half did not, suggesting other biological mechanisms may be involved. This result highlights the need for new biomarkers to be discovered to predict treatment response in future studies.

This case series is the largest focused exclusively on exceptional immunotherapy responders in pancreatic cancer. By excluding patients who received chemotherapy, the study isolates the effects of immune-based drugs, including PD-1 inhibitors such as pembrolizumab and nivolumab, CTLA-4 inhibitors like ipilimumab, and agents targeting macrophages.

While the sample size is small, the findings challenge the assumption that immunotherapy is ineffective for nearly all pancreatic cancer patients. The study suggests that, under certain biological conditions, this treatment can be remarkably successful. Further research is needed to understand the underlying mechanisms.

This work supports the need to reconsider how clinical trials are designed for pancreatic cancer and who is eligible for immunotherapy. Broader criteria and more personalized molecular profiling could help uncover hidden opportunities for treatment in this highly lethal cancer.

DOI - https://doi.org/10.18632/oncotarget.28739

Correspondence to - Jordan M. Winter - jordan.winter@UHHospitals.org

Video short - https://www.youtube.com/watch?v=VeWTcuVmqgM

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28739

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

MEDIA@IMPACTJOURNALS.COM

Oncotarget

Rare Pancreatic Cancer Patients Show Strong Response to Immunotherapy

Why does eating more not fix the severe weight loss seen in some cancer patients, and what can be done about it?

In this 'Ask Me Anything' episode, Dr Hui-Ling Ou, Programme Manager for the Pancreatic Cancer and Cancer Immunology Programmes at the CRUK Cambridge Centre, speaks with researchers from the Cancer Cachexia Action Network (CANCAN): Dr Claire Connell (University of Cambridge and Cambridge University Hospitals NHS Foundation Trust), Dr David Lewis (CRUK Scotland Institute), and Dr Tobias Janowitz (Cold Spring Harbor Laboratory).

Together, they unpack what cancer-associated cachexia is, why it's so devastating for patients, and how scientists are working to understand and reverse this syndrome. The guests share how their research, spanning metabolism, imaging, immunology, and clinical studies, is bringing fresh insights and hope to a problem that affects quality of life for so many.

This thought-provoking discussion shines a light on the collaborative efforts driving progress against one of cancer's most challenging complications.

Ask me anything about cancer

Ask me anything about... the science of cancer-associated cachexia

What do you most want to know about pancreatic cancer and cancer-associated cachexia?

In this special episode, we bring you a recording of a live 'Ask Me Anything (AMA)' event hosted by the CRUK Cambridge Centre Pancreatic Cancer Programme for World Pancreatic Cancer Day 2024.

A multidisciplinary and international panel of experts, including clinicians, researchers, nurses, dietitians and physiotherapists, answer thoughtful questions from the public about pancreatic cancer, cachexia and the latest research and care approaches. Topics range from understanding the biology of these diseases to managing symptoms and improving quality of life.

The discussion sheds light on the progress being made and the ongoing challenges in improving outcomes for people affected by these conditions.

Ask me anything about... cachexia research and management

Immunotherapy is not usually effective against pancreatic cancer (PC), but a new study published in Oncotarget (Volume 16, 2025) highlights rare cases where it did help. These examples, though uncommon, may offer valuable insights for future treatment.

Pancreatic Cancer and Immunotherapy

Pancreatic cancer is often diagnosed at an advanced stage, which limits treatment options and contributes to its poor prognosis. While chemotherapy remains the standard treatment, it usually offers only modest benefits in terms of survival. Immunotherapy—an approach that activates the immune system to fight cancer—has been effective in other cancers but has shown limited success in PC.

This is largely due to the tumor’s ability to suppress immune responses and create an environment that protects it from attack. Currently, these drugs are only approved for a small subset of patients whose tumors have a specific genetic feature called high microsatellite instability (MSI-high), found in just 1 to 2 percent of cases.

The Study: Pancreatic Cancer Immunotherapy Responders

The study, titled “Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence,” was led by first author Kavin Sugumar and corresponding author Jordan M. Winter, from University Hospitals Seidman Cancer Center. 

The researchers examined medical records from 14 patients with pancreatic ductal adenocarcinoma (PDAC) who had responded unexpectedly well to immune checkpoint inhibitors—drugs that help reactivate immune cells to attack cancer. The drugs included PD-1 inhibitors such as pembrolizumab and nivolumab, CTLA-4 inhibitors like ipilimumab, and agents targeting tumor-associated macrophages. To find these rare cases, the research team contacted 471 oncologists from 91 major U.S. cancer centers between 2020 and 2021.

Full blog - https://www.oncotarget.org/2025/09/11/immunotherapy-response-in-pancreatic-cancer-what-a-new-study-reveals/

Paper DOI - https://doi.org/10.18632/oncotarget.28739

Correspondence to - Jordan M. Winter - jordan.winter@UHHospitals.org

Abstract video - https://www.youtube.com/watch?v=VeWTcuVmqgM

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28739

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, pancreatic adenocarcinoma, immunotherapy, exceptional responders, microsatellite instability, survival

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

MEDIA@IMPACTJOURNALS.COM

Immunotherapy Response in Pancreatic Cancer: What a New Study Reveals

NÜ TRAP

pancreas

pancreas +ketcomma

4. mars 2026

I denne episoden er Per Walday, CEO i Exact Therapeutics, tilbake i studio for en oppdatering om selskapet. Exact Therapeutics er et norsk biotekselskap som utvikler en ultralydbasert teknologi kalt Acoustic Cluster Therapy (ACT), som brukes til å levere kreftlegemidler mer presist inn i svulster.

Samtalen dreier seg i stor grad om ENACT-studien – en pågående fase 2-klinisk studie i bukspyttkjertelkreft, en av de vanskeligste kreftformene å behandle. 

Per forteller om den positive sikkerhetsavlesningen fra studien i slutten av januar 2026, som utløste en forhåndsavtalt finansieringsmekanisme der investorene valgte å kjøpe seg ytterligere opp i selskapet. Hele 96 % benyttet seg av denne muligheten, og selskapet fikk inn 60 millioner kroner.

Vi snakker også om veien videre for selskapet, og hvilke milepæler som kommer framover. 

Neste uke skal Jónas og Elisabeth ha en nyhetsoppdatering, der vi særlig snakker om de gode nyhetene fra Photocure og Cevira. Send oss gjerne spørsmål!

Episode 349: Exact Therapeutics med Per Walday

Episódio 164º
Série: Saúde e Espiritualidade - (Pâncreas)

ESSE PODCAST É UM PROJETO DA IPB RIO PRETO:
INSTAGRAM: https://www.instagram.com/ipriopreto/ 
SOUNDCLOUD: https://soundcloud.com/ipriopreto/sets/calvinamente

MESA COMPOSTA POR:
🎙️Reverendo Robson Odirlei Ferreira
 https://www.instagram.com/robson.odirlei.ferreira/
🎙️Felipe Carvalho
https://www.instagram.com/felipedocarvalhoo/
🎙️Eduardo Roberto Conceição
https://www.instagram.com/edusemisul/
🎙️Presb. Dr Henrique Gandolfi
https://www.instagram.com/drhenriquegandolfi/

CÂMERAS - ÁUDIO - MÍDIAS SOCIAIS
🎬 Fábio Vizintim
https://www.instagram.com/diaconofabiovizintim/
🎬 Gustavo Fávero
https://www.instagram.com/dr.gustavofavero/

LOCALIZAÇÃO DA NOSSA IGREJA
Rua Prudente de Moraes 2664, Boa Vista.
Caminho para chegar à igreja: https://bit.ly/49C3SPC

Secretaria: +55 (17) 32141410
WhatsApp: https://wa.me/5517996127769
Contatos: https://bit.ly/3QWf9TJ

CULTOS:
AOS DOMINGOS
Culto da manhã: 9h
Escola Bíblica Dominical: 10h
Culto da noite: 19h

ÀS QUARTAS
Culto de Oração: 20h

0164 CalvinaMente: Pâncreas em pauta

Pancreas Express

惨澹 🌍🧸
baby venus
 ✦. ִ ࣪𖤐. ˚₊‧꒰ა ☆ ໒꒱ ‧₊

ACEP Frontline, hosted by Dr. Ryan Stanton, features in-depth conversations on the hottest topics in emergency medicine and critical care.

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.

Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/

Aging is dedicated to advancing our understanding of the biological mechanisms that drive aging and the development of age-related diseases. Our mission is to serve as a platform for high-quality research that uncovers the cellular, molecular, and systemic processes underlying aging, and translates these insights into strategies to extend healthspan and delay the onset of chronic disease.

Read about the Aging Scientific Integrity Process: https://aging-us.com/scientific-integrity

Radium er en podkast som utgis av RADFORSK. I studio snakker Elisabeth Andersen og Jónas Einarsson om siste nytt innen kreftforskning og utvikling av ny kreftbehandling og porteføljebedriftene til RADFORSK - alene eller sammen med gjester.

Sermões, aulas e materiais em áudio da Igreja Presbiteriana de São José do Rio Preto

Physician and surgeon, writer, and composer exploring themes of reflection, survival, healing, love, and human connection.

This work spans music, storytelling, and narrative pieces created for moments of quiet attention—during recovery, late nights, childhood, caregiving, grief, hope, and resilience. Some tracks are written for children, some for adults, and many for the spaces in between, where memory and emotion overlap.

As a physician, I am drawn to the ways people endure, adapt, and heal. As a writer, I focus on human relationships, family, vulnerability, and the small moments that shape us. As a composer, I create music meant to accompany rather than dominate—music that can sit beside thought, rest, or reflection.

These pieces are not designed for performance or spectacle.
They are meant to keep company.

The Cancer Research UK Cambridge Centre unites over 1,000 world-leading biologists, chemists, physicists, engineers, mathematicians, computer scientists, clinicians, nurses and allied healthcare professionals from across Cambridge, UK to tackle cancer from every angle.

Our mission is to end death and disease caused by cancer through research, treatment and education. We are detecting cancer at its earliest stage and are developing personalised treatments for every patient through facilitating new collaborations and driving the translation of new scientific discoveries into clinical applications to improve patient care. By working together across a range of different disciplines, our members are breaking down the barriers between the laboratory and the clinic, enabling patients to benefit from the latest innovations in cancer science.

New tracks tagged #pancreas